|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.67 USD | -0.51% |
|
+0.46% | +12.14% |
| May. 14 | Transcript : Kiniksa Pharmaceuticals, Ltd. Presents at Bank of America Health Care Conference 2024, May-14-2024 10:40 AM | |
| Apr. 23 | Kiniksa Pharmaceuticals Q1 Loss Widens, Revenue Rises | MT |
Kiniksa Pharmaceuticals, Ltd. increased sales guidance for 2023. For the year, the company increased ARCALYST sales guidance from a range of $190 million to $205 million to $200 million to $215 million.
| 1st Jan change | Capi. | |
|---|---|---|
| +12.14% | 1.4B | |
| +9.58% | 115B | |
| +12.41% | 106B | |
| -2.59% | 21.96B | |
| -12.38% | 21.87B | |
| -5.29% | 19.21B | |
| -3.35% | 18.08B | |
| -38.57% | 17.71B | |
| +7.51% | 14.32B | |
| +35.67% | 12.42B |
KINIKSA PHARMACEUTICALS, LTD. 